 4D pharma PLC AIM:DDD, NASDAQ:LBPS said it will present an update from the phase III trial of its putative asthma treatment at an industry conference. The data will be delivered as a late-breaking abstract, which will underline the safety and efficacy of MRx-4DP0004. 